Navigation Links
Aethlon Medical Note: Marc Robins Joins the Aethlon Team
Date:4/25/2012

SAN DIEGO, April 25, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.

(Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

Aethlon Medical was originally formed to advance a medical device technology that targeted the removal of harmful metals from circulation.  At the time, our strategy to treat infectious disease was a mere seed of thought and we certainly didn't envision the opportunities that would emerge in cancer and sepsis.  Since those early days, Marc Robins has witnessed both the setbacks and advances in our quest to create innovative therapies to combat life-threatening conditions.

I am pleased to advise you that Marc has agreed to work with us to expand the awareness of our endeavors within the financial and medical community.  Additionally, he will provide our shareholders with an additional channel of communication.  Marc's unique understanding of medical technology (including the medical devices in our therapeutic pipeline) and the financial markets will help to ensure our message is properly communicated.  He is also a passionate AEMD shareholder with 35 years of experience in discovering and investing in micro-cap medical technology organizations.  Marc was a "Special Situation" columnist at FORBES magazine, the founding publisher of the The Red Chip Review, an analyst at E.F. Hutton, and a principal at The Robins Group, LLC, an institutional investment banking firm that once managed a financing that helped us advance clinical programs. Marc can be reached at (877) 276-2467 or by email at mr@aethlonmedical.com.

About Aethlon Medical

The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.

Contacts:

James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com

Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com

John P. Salvador
Director, Communications
858.459.7800 x307
jps@aethlonmedical.com


'/>"/>
SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
2. Aethlon Medical Reports Immediate and Rapid Virologic Responses in Hepatitis C (HCV) Patients Receiving Hemopurifier® Treatment Protocol
3. Aethlon Medical Establishes Sepsis & Inflammation Scientific Advisory Board
4. Aethlon Medical Discloses Availability of the Biotech Showcase™ 2012 Presentation
5. Aethlon Medical Announces Biotech Showcase™ 2012 Presentation
6. Aethlon Medical Announces Approval and Initiation of Cancer Research Study to Target Tumor-Secreted Exosomes
7. Aethlon Medical Releases Shareholder Letter
8. Aethlon Medical to Present at IN3 Medical Innovation Summit on October 27th
9. Aethlon Medical Announces Availability of its Exosome Detection Assay to the Research Community
10. Aethlon Medical Announces Hemopurifier® and HER2osome™ Cancer Therapy Presentation at Exosomes and Microvesicles 2011
11. "A Medical Device Strategy To Inhibit HER2+ Breast Cancer Progression" Released by Aethlon Medical, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 ... today announced preliminary safety and efficacy data from ... oral selective MDM2 inhibitor, suggesting that DS-3032 may ... relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... part of the phase 1 study of DS-3032 were ...
(Date:12/5/2016)... , Dec. 5, 2016 Eisai Inc. announced ... the 2016 Annual Meeting of the American Epilepsy Society ... is indicated as an adjunctive therapy for the treatment ... generalized seizures and primary generalized tonic-clonic seizures (PGTC) in ... and older. Please see Important Safety Information for FYCOMPA, ...
(Date:12/5/2016)... BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... candidates, presents positive Phase 2a correlative data, as well as ... at the ongoing 58th American Society of Hematology (ASH) Annual ... . ... As previously announced, in ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... ... Will Never Be The Same” is a fictional tale about growing up with the ... the creation of published author, Kim T. Briggs, a self-described “big kid” who has ... and philosophy from Judson University in Elgin, Illinois. Having written numerous Christian drama skits ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... ability of physical therapist assistants, under direct supervision of a licensed physical therapist, ... physical therapy receives a consultation and treatment plan from a licensed physical therapist ...
(Date:12/5/2016)... IL (PRWEB) , ... December 05, 2016 , ... The ... to the individual looking to buy neoprene knee sleeves for lifting and ... The design focuses heavily on two main aspects to provide a higher quality knee ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... an excellent way to ensure moisture measurements are consistently correct. However, regular ... , Now, METTLER TOLEDO offers a solution: SmartCal™ . This ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... they have teamed up with The American College of Surgeons (ACS) to provide ... on Trauma, the “Bleeding Control Basic” course is a pilot program that fulfills ...
Breaking Medicine News(10 mins):